Servier is an international pharmaceutical company governed by a foundation and headquartered in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth. More information: www.servier.com
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering.
We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 42,600 people in 75 countries and markets its products in more than 180 countries.
Bader Sultan & Brothers Company was established in 1960, and has ever since been building a strong reputation as a company
premised on growth, holistic solutions, quality control, international operations and corporate social responsibility.
Presenting Eli Lilly & BD. For 140 years, Eli Lilly worked tirelessly to develop and deliver trusted medicines that meet
real needs. Their growing portfolio of medicines includes treatments in the areas of oncology, cardiovascular, diabetes,
critical care, neuroscience, men’s health and musculoskeletal fields.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
MSD also known as Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. MSD has been present for over than 30 years in the GULF region. MSD GULF operates throughout offices based in the UAE, Kuwait, Bahrain, Qatar & Oman and ranks amongst the leading pharmaceutical companies throughout the GULF region. Through its local distributors, MSD GULF provides innovative medications in several disease entities. These include products for Anti- Infectives, Cardiovascular, Asthma & Allergy, Diabetes, HCV, HIV, Pain & Inflammation, Osteoporosis, Oncology, Fertility, Ophthalmic, and Anesthesia in addition to several specialized Vaccines.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit www.novartis.com